Molecular disruption of the MRN(95) complex induces radiation sensitivity in head and neck cancer.
OBJECTIVE
The goal of the project was to develop a novel treatment strategy for head and neck cancer that induces radiation sensitivity. We hypothesized that the normal cellular DNA repair response in head and neck squamous cell carcinoma after radiation therapy can be blocked by a dominant negative disruption of the functioning MRN(95) protein complex. To test this hypothesis, we have developed a novel molecular therapy that inhibits the MRN(95) complex in tumor cells. Disruption the MRN(95) complex and thus DNA repair should result in enhanced tumor killing after classic external-beam radiation therapy.


METHODS
Experiments with human head and neck squamous cell carcinoma cell lines in vitro were performed.


METHODS
Recombinant adenovirus vectors carrying the genes for enhancing radiation were generated. Human head and neck squamous cell carcinoma cells were treated with recombinant adenovirus vectors carrying the mutated p95 gene (p95-300), which contains the C-terminus 300 amino acids of the Nbs1(p95) protein. Tumor cells were also treated with adenovirus vector carrying full-length p95 protein or DL312 control virus; then all cell lines were subjected to 2 Gy irradiation. Cell growth curves were determined through colorimetric tetrazolium salt assay.


RESULTS
Both the Ad-p95-300 and Ad-p94-his (full-length wild-type gene) demonstrated significant antitumor effect alone and in combination with radiation therapy compared with control samples. Cell cycle analysis demonstrated a shift toward the G2/M phase of the cell cycle. Analysis of telomerase activity demonstrated a significant decrease in telomerase activity after molecular therapy alone, and a greater decrease when combined with radiation therapy.


CONCLUSIONS
Adenovirus-mediated mutant or full-length p95 molecular therapy demonstrated efficacy for the treatment of head and neck squamous cell carcinoma in vitro. This novel molecular therapy strategy induced significant radiation sensitization, induced a relative G2/M arrest, and decreased telomerase activity, all of which enhance the benefit of radiation therapy.
O'Malley
Bert W
BW
Department of Otolaryngology--Head and Neck Cancer, University of Maryland School of Medicine, Baltimore, USA. bomalley@smail.umaryland.edu
Li
Daqing
D
Carney
James
J
Rhee
Joung
J
Suntharalingam
Mohan
M
D000256:Adenoviridae / Q000235:genetics; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000532:radiotherapy*; D018797:Cell Cycle Proteins / Q000235:genetics*; D002470:Cell Survival / Q000235:genetics / Q000528:radiation effects*; D018389:Codon, Nonsense / Q000235:genetics; D004260:DNA Repair / Q000235:genetics / Q000528:radiation effects; D004268:DNA-Binding Proteins / Q000235:genetics*; D016195:G2 Phase / Q000235:genetics / Q000528:radiation effects; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D006801:Humans; D000076228:MRE11 Homologue Protein; D009687:Nuclear Proteins / Q000235:genetics*; D010039:Otorhinolaryngologic Neoplasms / Q000235:genetics* / Q000532:radiotherapy*; D011836:Radiation Tolerance / Q000235:genetics*; D019098:Telomerase / Q000378:metabolism; D019076:Transgenes / Q000235:genetics; D014407:Tumor Cells, Cultured / Q000473:pathology / Q000528:radiation effects*
D018797:Cell Cycle Proteins; D018389:Codon, Nonsense; D004268:DNA-Binding Proteins; C121766:MRE11 protein, human; C112156:NBN protein, human; D009687:Nuclear Proteins; D019098:Telomerase; D000076228:MRE11 Homologue Protein